NeoCura

NeoCura, founded in 2017, is characterized by AI-powered RNA drug development and is committed to becoming an internationally leading RNA innovative drug research and development enterprise. The company has built a multi-omics big data collection platform and multiple bio-omics databases, utilizing AI and bioinformatics technologies for in-depth drug target discovery and fully automated drug design for innovative RNA drug research. NeoCura has gathered a top-tier scientific research team with a global perspective, including dozens of PhDs/Postdocs from Harvard, Cambridge, Cornell, Peking University, Tsinghua University, and the Chinese Academy of Sciences. The team includes experts in AI bioinformatics, tumor immunology, novel vaccine development, drug delivery, and nucleic acid carriers. Its R&D pipeline covers multiple directions such as tumor vaccines, tumor microenvironment immunomodulators, and viral vaccines. A leading RNA drug production center in China has been established to support pipeline R&D and clinical needs. With its cutting-edge AI technology, robust R&D pipeline, and outstanding innovation capabilities, NeoCura has successively been honored as "China's Most Promising Enterprise in 2021" and among the "Top 10 Innovative Enterprises in AI/Computational Drug Discovery in China in 2021."